Tezepelumab helps severe asthma patients reduce oral steroids over 28 weeks
· Medical Xpressedited by Sadie Harley, reviewed by Andrew Zinin
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Lead Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
New results from the Phase III SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term oral corticosteroid use in adults with severe oral corticosteroid-dependent asthma while maintaining asthma control and improving key clinical outcomes. The findings were published in The Lancet Respiratory Medicine.
The multicenter, double-blind, placebo-controlled study evaluated adults with severe asthma who rely on daily oral corticosteroids despite treatment with high-dose inhaled therapies. Patients treated with tezepelumab were nearly three times more likely than those receiving a placebo to achieve greater reductions in their daily oral corticosteroid dose while maintaining asthma control.
"Long-term oral corticosteroid use can have devastating consequences for patients, including diabetes, osteoporosis, cardiovascular disease, and significant impacts on quality of life," said Michael Wechsler, MD, lead author on the study and director of the Cohen Family Asthma Institute at National Jewish Health.
"These findings are important because they show that patients with severe asthma treated with tezepelumab may be able to substantially reduce their dependence on oral steroids without sacrificing asthma control."
Over the 28-week treatment period, 69% of patients receiving tezepelumab achieved at least a 50% reduction in oral corticosteroid dose compared to 44% of patients receiving the placebo.
In addition, 35% of patients treated with tezepelumab were able to completely stop use of oral corticosteroids, compared to 21% in the placebo group.
Publication details
Michael E Wechsler et al, Efficacy and safety of tezepelumab versus placebo in reducing oral corticosteroid use in adults with severe, oral corticosteroid-dependent asthma (SUNRISE): a multicentre, placebo-controlled, double-blind, phase 3 trial, The Lancet Respiratory Medicine (2026). DOI: 10.1016/s2213-2600(26)00076-7
Journal information: Lancet Respiratory Medicine
Key medical concepts
severe asthmatezepelumabClinical Trials, Phase III as TopicDiabetes
Clinical categories
Pulmonary medicineAllergy and immunologyCommon illnesses & PreventionClinical pharmacology Provided by National Jewish Health Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Tezepelumab helps severe asthma patients reduce oral steroids over 28 weeks (2026, May 30) retrieved 30 May 2026 from https://medicalxpress.com/news/2026-05-tezepelumab-severe-asthma-patients-oral.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.